Background: Interleukin-13 (IL-13) has been implicated in the pathogenesis of fibrotic conditions. Previously, a murine model for scleroderma has been established by repeated local injections of bleomycin. This animal model enabled us to study local expression and production of IL-13 in skin lesions during disease progression. Methods: Dermal sclerosis (DSc) was induced by repeated subcutaneous injections of bleomycin (1 mg/ml) in C3H/HeJ mice. IL-13 and IL-4 expressions were examined by RT-PCR, ELISA and immunohistochemistry. Results: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment. Quantification by densitometry revealed up to 4.2- and 1.9-fold increases, respectively. Immunohistochemical localization showed in skin lesions expression of IL-13 on infiltrating inflammatory cells, including mononuclear cells and possibly mast cells, increased with DSc progression. IL-13 protein production was also significantly increased. In skin lesions, IL-13 receptor (IL-13R) α2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure. IL-13Rα2, but not IL-13Rα1, mRNA was upregulated in the whole skin after 4 weeks. On the contrary, mRNA expression of IL-13Rα1 and IL- 13Rα2 was significantly altered in the cultured fibroblasts derived from bleomycin-treated skin. Conclusion: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.

Keywords:
Animal model, Bleomycin, Interleukin-13, Interleukin-13 receptor, Scleroderma
1.
Krieg T, Meurer M: Systemic scleroderma: Clinical and pathophysiological aspects. J Am Acad Dermatol 1988;18:457–481.
2.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis. J Rheumatol 1988;25:189–195.
3.
Fleischmajer R, Perlish JS, Reeves IRT: Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977;20:975–984.
4.
Gruschwitz MS, Moormann S, Kromer G, Sgonc R, Dietrich H, Boeck G, Gershwin ME, Boyd R, Wick G: Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun 1991;4:577–593.
5.
Jaffee BD, Claman HN: Chronic graft-versus-host disease (GVHD) as a model for scleroderma. 1. Description of model system. Cell Immunol 1983;77:1–12.
6.
Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138–146.
7.
Needlemann BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1985;28:775–780.
8.
de Vries JE: The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998;102:165–169.
9.
Minty A, Asselin S, Bensussan A, Shire D, Vita N, Vyakarnam A, Wijdenes J, Ferrara P, Caput D: The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur Cytokine Netw 1997;8:203–213.
10.
Zurawski G, de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19–26.
11.
Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328–332.
12.
Chiramonte MG, Donaldson DD, Cheever AW, Wynn TA: An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777–785.
13.
Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN: Schistosoma infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000;164:2585–2591.
14.
Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA: IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999;162:920–930.
15.
Hancock A, Armstrong L, Gama R, Millar A: Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998;18:60–65.
16.
Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B: IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998;10:1421–1433.
17.
Zhu Z, Homer RJ, Wang Z, Chen O, Geba GP, Wang Y, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation mucus hypersecretion subepithelial fibrosis, physiologic abnormalities and eotaxin production. J Clin Invest 1999;103:779–788.
18.
Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988–994.
19.
Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med 2001;194:809–821.
20.
Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, Dent G, Holgate ST, Davies DE: The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001;25:385–391.
21.
Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B: Interleukin (IL)-4 and IL-13 act on human lung fibroblasts. J Clin Invest 1998;101:2129–2139.
22.
Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA, Keane MP: Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002;27:419–427.
23.
Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456–462.
24.
Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K: Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/WV mice. J Rheumatol 1999;26:2628–2634.
25.
Yamamoto T, Kuroda M, Takagawa S, Nishioka K: Animal model of sclerotic skin. III. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000;292:535–541.
26.
Yamamoto T, Nishioka K: Animal model of sclerotic skin. IV. Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001;117:999–1001.
27.
Yamamoto T, Nishioka K: Animal model of sclerotic skin. V. Increased expression of α-smooth muscle actin in fibroblastic cells in the lesional skin of bleomycin-induced scleroderma. Clin Immunol 2002;102:77–83.
28.
Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479–1485.
29.
Gillery P, Fertin C, Nicolas JF, Chasang F, Kalis B, Banchereau J, Maquart FX: Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures: Potential role in fibrosis. FEBS Lett 1992;302:231–234.
30.
Sempowski GD, Beckmann MP, Derdak S, Phipps RP: Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors: Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol 1994;152:3606–3614.
31.
Duncan MR, Berman B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686–692.
32.
Feghali CA, Bost KL, Boulware DW, Levy LS: Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. Clin Immunol Immunopathol 1992;63:182–197.
33.
Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, Di Franco M, Taccari E, Valesini G: Interleukin-13 in systemic sclerosis: Relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 2003;22:102–106.
34.
Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K: Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003;207:141–147.
35.
Ishikawa O, Ishikawa H: Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992;19:1202–1206.
36.
Hawkins RA, Claman HN, Clark RAF, Steigerwald JC: Increased dermal mast cell populations in progressive systemic sclerosis: A link in chronic fibrosis? Ann Intern Med 1985;102:1182–1186.
37.
Nishioka K, KobayashiY, Katayama I, Takijiri C: Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987;123:205–208.
38.
Murata T, Obiri NI, Debinski W, Puri RK: Structure of IL-13 receptor: Analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90–94.
39.
Toru H, Pawankar R, Ra C, Yata J, Nakahata T: Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: Enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol 1998;102:491–502.
40.
Murata T, Husain SR, Mohri H, Puri RK: Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998;10:1103–1110.
41.
Kawakami K, Taguchi J, Murata T, Puri RK: The interleukin-13 receptor α2 chain: An essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673–2679.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.